<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>LEVSIN- hyoscyamine sulfate injection, solution </strong><br>Alaven Pharmaceutical LLC<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>Levsin® injection <br>(hyoscyamine sulfate injection USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Levsin® injection (hyoscyamine sulfate injection USP) is a sterile solution containing 0.5 mg hyoscyamine sulfate per mL in water for injection.</p>						Levsin® is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids. The empirical formula is (C<span class="Sub">17</span>H<span class="Sub">23</span>NO<span class="Sub">3</span>)<span class="Sub">2</span>•H<span class="Sub">2</span>SO<span class="Sub">4</span>•2H<span class="Sub">2</span>O and the molecular weight is 712.85. Chemically, it is benzeneacetic acid, α-(hydroxymethyl)-,8-methyl-8-azabicyclo [3.2.1.] oct-3-yl ester, [3(S)-endo]-, sulfate (2:1), dihydrate with the following structure: 						<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd2e786c-29a7-40f8-a5f3-7641413f5036&amp;name=levsin-01.jpg"></div>
<p>The 1 mL ampuls contain as inactive ingredients: water for injection, pH is adjusted with hydrochloric acid when necessary.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Levsin® inhibits specifically the actions of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of the smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, and the exocrine glands. It is completely devoid of any action in the autonomic ganglia. Levsin® inhibits gastrointestinal propulsive motility and decreases gastric acid secretion. Levsin® also controls excessive pharyngeal, tracheal and bronchial secretions.</p>
<p>Levsin® disappears rapidly from the blood and is distributed throughout the entire body. The half-life of Levsin® is 3½ hours. Levsin® is partly hydrolyzed to tropic acid and tropine but the majority of the drug is excreted in the urine unchanged within the first 12 hours. Only traces of this drug are found in breast milk. Levsin® passes the blood brain barrier and the placental barrier.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Levsin® is effective as adjunctive therapy in the treatment of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>. In acute episodes, Levsin® injection can be used to control gastric secretion, visceral spasm and hypermotility in spastic <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, spastic bladder, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, pylorospasm, and associated <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>. For use as adjunctive therapy in the treatment of <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (<span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable colon</span>, <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">spastic colon</span>, <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">mucous colitis</span>) and functional <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>. Also as adjunctive therapy in the treatment of <span class="product-label-link" type="condition" conceptid="199075" conceptname="Neurogenic bladder">neurogenic bladder</span> and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Parenterally administered Levsin® is also effective in reducing gastrointestinal motility to facilitate diagnostic procedures such as endoscopy or hypotonic duodenography. Levsin® may be used to reduce <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and hypersecretion in <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, in certain cases of partial <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> associated with vagal activity, and as an antidote for <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> by anticholinesterase agents.</p>
<dl>
<dt>  </dt>
<dd>IN ANESTHESIA:</dd>
<dt>  </dt>
<dd>Levsin® injection is indicated as a pre-operative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and acidity of gastric secretions, and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. Levsin® protects against the peripheral <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">muscarinic effects</span> such as <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and excessive secretions produced by halogenated hydrocarbons and cholinergic agents such as physostigmine, neostigmine, and pyridostigmine given to reverse the actions of curariform agents.</dd>
<dt>  </dt>
<dd>IN UROLOGY:</dd>
<dt>  </dt>
<dd>Levsin® injection may also be used intravenously to improve radiologic visibility of the kidneys. It is also indicated along with morphine or other narcotics in symptomatic relief of biliary and <span class="product-label-link" type="condition" conceptid="201690" conceptname="Renal colic">renal colic</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>; <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">obstructive uropathy</span> (for example, <span class="product-label-link" type="condition" conceptid="433813" conceptname="Bladder neck obstruction">bladder neck obstruction</span> due to <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis); <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, intestinal atony of elderly or debilitated patients; unstable cardiovascular status in acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>; severe <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>; toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span> complicating <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>; <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In the presence of high environmental temperature, <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span> can occur with drug use (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span> due to decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>). <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> may be an early symptom of incomplete <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful. Like other anticholinergic agents, Levsin® may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug.</p>
<p><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> has been reported in sensitive individuals given anticholinergic drugs. CNS signs and symptoms include <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4084412" conceptname="Poor short-term memory">short term memory loss</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, decreased <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and mannerisms, and <span class="product-label-link" type="condition" conceptid="4154304" conceptname="Inappropriate affect">inappropriate affect</span>. These CNS signs and symptoms usually resolve within 12-48 hours after discontinuation of the drug.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Use with caution in patients with: <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, coronary heart disease, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Investigate any <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> before giving any anticholinergic drug since they may increase the heart rate. Use with caution in patients with <span class="product-label-link" type="condition" conceptid="4224004" conceptname="Hiatal hernia">hiatal hernia</span> associated with <span class="product-label-link" type="condition" conceptid="30437" conceptname="Gastro-esophageal reflux disease with esophagitis">reflux esophagitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Levsin® may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>; patients should observe caution before driving, using machinery or performing other tasks requiring mental alertness.</p>
<p>Use of Levsin® may decrease <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> resulting in <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>; febrile patients or those who may be exposed to elevated environmental temperatures should use caution.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Additive adverse effects resulting from cholinergic blockade may occur when Levsin® is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term studies in animals have been performed to determine the carcinogenic, mutagenic or impairment of fertility potential of Levsin®; however, over 30 years of marketing experience shows no demonstrable evidence of a problem.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">Animal reproduction studies have not been conducted with Levsin®. It is also not known whether Levsin® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Levsin® should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Levsin® is excreted in human milk. Caution should be exercised when Levsin® is administered to a nursing woman.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Not all of the following adverse reactions have been reported with hyoscyamine sulfate. The following adverse reactions have been reported for pharmacologically similar drugs with anticholinergic/antispasmodic action. Adverse reactions may include dryness of the mouth; <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitancy</span> and retention; <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>; <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>; <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>; <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span>; increased ocular <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>; <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span>; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>; <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>; suppression of lactation; <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">bloated feeling</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> or drug idiosyncrasies; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and other dermal manifestations; <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>; speech disturbance; some degree of <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span> and/or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> (especially in elderly persons); and decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The signs and symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">hot dry skin</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, dryness of the mouth, difficulty in swallowing, and CNS stimulation.</p>
<p>Measures to be taken are immediate lavage of the stomach and injection of physostigmine 0.5 to 2 mg intravenously and repeated as necessary up to a total of 5 mg. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> may be treated symptomatically (tepid water sponge baths, hypothermic blanket). <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Excitement</span> to a degree which demands attention may be managed with sodium thiopental 2% solution given slowly intravenously or chloral hydrate (100-200 mL of a 2% solution) by rectal infusion. In the event of progression of the curare-like effect to <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns.</p>
<p>In rats, the LD<span class="Sub">50</span> for hyoscyamine is 375 mg/kg. Levsin® is dialyzable.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dose may be administered subcutaneously, intramuscularly, or intravenously without dilution. As with all parenteral drug products, Levsin® injection should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></h2>
<p class="First">The usual adult recommended dose is 0.5 to 1 mL (0.25 to 0.5 mg). Some patients may need only a single dose; others may require administration two, three, or four times a day at four hour intervals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Diagnostic Procedures</h2>
<p class="First">The usual adult recommended dose is 0.5 to 1 mL (0.25 to 0.5 mg) administered intravenously 5 to 10 minutes prior to the diagnostic procedure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>Anesthesia</h2>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.1"></a><p></p>
<h3>Adults and pediatric patients over 2 years of age</h3>
<p class="First">As a pre-anesthetic medication, the recommended dose is 5 µg (0.005 mg) per kg of body weight. This dose is usually given thirty to sixty minutes prior to the anticipated time of induction of anesthesia or at the time the pre-anesthetic narcotic or sedatives are administered.</p>
<p>Levsin® injection may be used during surgery to reduce drug-induced <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. It should be administered intravenously in increments of 0.25 mL and repeated as needed.</p>
<p>To achieve reversal of <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span>, the recommended dose is 0.2 mg (0.4 mL) Levsin® injection for every 1 mg neostigmine or the equivalent dose of physostigmine or pyridostigmine.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Levsin® injection (hyoscyamine sulfate injection USP, 0.5 mg/mL), is available in 1 mL ampuls.</p>
<dl>
<dt>  </dt>
<dd>1 mL ampuls — Box of 5           NDC 68220-111-05</dd>
</dl>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First">Store at controlled room temperature 15°-30°C (59°-86°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Also available as:</p>
<table width="80%">
<col align="left" valign="bottom" width="40%">
<col align="left" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead><tr class="First Last">
<th align="left">Levsin<span class="Sup">®</span>
</th>
<th align="left">Dosage <br>Strength</th>
<th align="center">Package <br>Size</th>
<th align="center">NDC</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Tablets</td>
<td align="left">0.125mg</td>
<td align="center">100</td>
<td align="center">68220-112-10</td>
</tr>
<tr>
<td align="left">Tablets</td>
<td align="left">0.125mg</td>
<td align="center">500</td>
<td align="center">68220-112-50</td>
</tr>
<tr>
<td align="left">Sub-lingual Tablets</td>
<td align="left">0.125mg</td>
<td align="center">100</td>
<td align="center">68220-113-10</td>
</tr>
<tr>
<td align="left">Sub-lingual Tablets</td>
<td align="left">0.125mg</td>
<td align="center">500</td>
<td align="center">68220-113-50</td>
</tr>
<tr>
<td align="left">Elixir</td>
<td align="left">0.125mg/5 mL</td>
<td align="center">Pint</td>
<td align="center">0091-4532-16</td>
</tr>
<tr>
<td align="left">Drops</td>
<td align="left">0.125mg/mL</td>
<td align="center">15mL</td>
<td align="center">0091-4538-15</td>
</tr>
<tr>
<td align="left">Injection</td>
<td align="left">0.5mg/mL</td>
<td align="center">Box of 5-1mL</td>
<td align="center">68220-111-05</td>
</tr>
<tr>
<td align="left">Levbid® extended-</td>
<td align="left">0.375mg</td>
<td align="center">100</td>
<td align="center">68220-115-10</td>
</tr>
<tr class="Last">
<td align="left">release tablets</td>
<td align="left">0.375mg</td>
<td align="center">500</td>
<td align="center">68220-115-50</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd2e786c-29a7-40f8-a5f3-7641413f5036&amp;name=levsin-02.jpg"></p>
<p>Marietta, GA 30067</p>
<p>Address medical inquiries to: <br>Alaven Pharmaceutical LLC <br>2260 Northwest Parkway, Suite A <br>Marietta, GA 30067</p>
<p>Or call toll free 1-888-317-0001</p>
<p>By: Akorn Inc. <br>Decatur, IL 62522, USA</p>
<p>PC2952B <br>07/08</p>
<p>Printed in USA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 0.5 mg Carton</h1>
<p class="First"><span class="Bold">NDC</span> 68220-111-05</p>
<p><span class="Bold">levsin<span class="Sup">®</span> injection</span><br>(hyoscyamine sulfate injection USP)</p>
<p><span class="Bold">0.5 mg</span> hyoscyamine sulfate USP <br>per mL in water for injection.</p>
<p>Rx only</p>
<p><span class="Bold">ALAVEN<span class="Sup">®</span></span><br>PHARMACEUTICAL LLC</p>
<p>For medical inquiries, call 1-888-317-0001</p>
<p><span class="Bold">5-1 mL <br>ampuls</span></p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd2e786c-29a7-40f8-a5f3-7641413f5036&amp;name=levsin-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVSIN 		
					</strong><br><span class="contentTableReg">hyoscyamine sulfate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68220-111</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYOSCYAMINE SULFATE</strong> (HYOSCYAMINE) </td>
<td class="formItem">HYOSCYAMINE SULFATE</td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68220-111-05</td>
<td class="formItem">5  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">UNAPPROVED DRUG OTHER</td>
<td class="formItem"></td>
<td class="formItem">12/01/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alaven Pharmaceutical LLC
							(140210829)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Akorn, Inc. (063434679)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Akorn, Inc.</td>
<td class="formItem"></td>
<td class="formItem">063434679</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>034da52b-7d64-4126-b918-3df9eb478ba2</div>
<div>Set id: dd2e786c-29a7-40f8-a5f3-7641413f5036</div>
<div>Version: 1</div>
<div>Effective Time: 20091208</div>
</div>
</div> <div class="DistributorName">Alaven Pharmaceutical LLC</div></p>
</body></html>
